Repository logo
 

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Background: Estimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in risk estimation when incorporating breast density and polygenic risk score (PRS) into the baseline cancer risk assessment and compared the efficacy of 2 risk-assessment delivery models. Methods: This 2-step study included 663 healthy women with a family history of breast cancer in which no pathogenic variants were identified. First, breast density and PRS were added to the baseline risk assessment for all participants. A randomized intervention study compared 2 delivery models (in-person vs pre-recorded video) for risk assessment in women at moderate or average risk. All tests were 2-sided. Results: Breast density and PRS reclassified the risk group into 33% of the participants, with only 5% reclassified as high-risk. After disclosure of their estimated multifactorial risk, 65% of women aligned their risk perception with their estimated risk, compared to 47% at baseline (P < .05). No statistically significant differences were found in the primary endpoint cancer worry, mean = 10.2 (SD = 3.1) vs 10.1 (2.7), between delivery models. In-person delivery had slightly better psychological outcomes (excluding the primary outcome) and higher satisfaction, though few participants in the video group sought in-person clarification. Conclusions: Incorporating breast density and PRS into risk assessments led to substantial reclassification, with 1 in 5 women facing de-escalated surveillance. Personalized assessments improve objective perceptions alignment. A model using a pre-recorded video-based model matches in-person delivery for moderate and average-risk women and is scalable for population-level implementation.

Description

Acknowledgements: We would like to thank Andrea Pérez for her help with patient recruitment, Bianca Pont for her support in developing the pre-recorded video and audio materials, and Doug Easton for the technical overview. The funders did not play a role in the design of the study; the collection, analysis, or interpretation of the data; writing of the manuscript; or the decision to submit the manuscript for publication.


Funder: European Union; doi: https://doi.org/10.13039/501100000780


Funder: Generalitat de Catalunya; doi: https://doi.org/10.13039/501100002809


Funder: State Agency for Research


Funder: Agencia Estatal de Investigación; doi: https://doi.org/10.13039/501100011033


Funder: Cellex Foundation; doi: https://doi.org/10.13039/100008050


Funder: Government of Canada; doi: https://doi.org/10.13039/501100000023

Keywords

Journal Title

JNCI: Journal of the National Cancer Institute

Conference Name

Journal ISSN

0027-8874
1460-2105

Volume Title

117

Publisher

Oxford University Press

Rights and licensing

Except where otherwised noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Sponsorship
Instituto de Salud Carlos III (PI19/01195, PI23/01047, PI23/00017, PI19/00553)
Breast Cancer Research Foundation (BCRF-23-203)
Secretariat for Universities and Research of the Department of Business and Knowledge (2021SGR01112)
Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033)
Cancer Research UK (PPRPGM-Nov20\100002)
Genome Canada (#13529)
Canadian Institutes of Health Research (#155865)